| Budget Amount *help |
¥433,420,000 (Direct Cost: ¥333,400,000、Indirect Cost: ¥100,020,000)
Fiscal Year 2014: ¥80,730,000 (Direct Cost: ¥62,100,000、Indirect Cost: ¥18,630,000)
Fiscal Year 2013: ¥82,290,000 (Direct Cost: ¥63,300,000、Indirect Cost: ¥18,990,000)
Fiscal Year 2012: ¥88,400,000 (Direct Cost: ¥68,000,000、Indirect Cost: ¥20,400,000)
Fiscal Year 2011: ¥87,490,000 (Direct Cost: ¥67,300,000、Indirect Cost: ¥20,190,000)
Fiscal Year 2010: ¥94,510,000 (Direct Cost: ¥72,700,000、Indirect Cost: ¥21,810,000)
|
|---|
| Outline of Final Research Achievements |
We have studied the roles of transforming growth factor (TGF)-beta and its related proteins (bone morphogenetic proteins, BMPs) on cancer microenvironment, by using molecular and cellular biological methods as well as recent genome biological techniques and biomaterials. We have investigated the molecular mechanisms involved in the induction of epithelial-mesenchymal transition (EMT) induced by TGF-beta, and found that functional interaction between cancer cells and cancer microenvironment plays important roles in the progression of cancer. We have also found that BMP-9 acts on lymphatic endothelial cells and inhibits lymphangiogenesis in vivo. Since anti-cancer drugs targeting cancer microenvironment are often less toxic than conventional anti-cancer drugs, our findings may be important for future development of new strategies for cancer diagnosis and treatment.
|
